Medicare to cover costs of new test for AR-V7


We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018.

The full media release and related information about the test itself are available on the Genomic Health corporate web site.

Basically, this is a test designed to assist you and your doctor to know whether you may have a specific genetic mutation known as AR-V7 that is associated with whether — if you have mCROPC — you are or are not a good candidate for treatment with drugs like enzalutamide and abiraterone acetate. If you are not a good candidate for treatment with one of these drugs, you may be wiser to get treatment with taxane-based chemotherapy.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: